Wistron Corporation has been actively in internal organizational transformation. In 2016, Wistron Medical Tech Holding Company was established to invest in the integration of biomedical technology and to develop biotechnology-related venture capital. Wistron Medical Technology (WMT), as an 100% invested subsidiaries, focuses on the medical field, expanding the advantages of design, production and manufacturing to high-end medical equipment, and assisting in the field of information, digital and intelligent solutions in the medical field, providing Human-centered smart medical processes and services. Now it comes some good news! By using the technology, WMT may change the stereotype of traditional medicine, and hope to create a new era of smart medical technology in Taiwan.

Data Analysis and AI Application in the Medical Field

Wistron Medical Technology (WMT) is a pioneer in intelligent applications. It has a diverse data science team able to deal with forms of Data like voice, imaging, and text. With strong software and hardware R & D capabilities, combined with the world's top medical consultants, and working with medical institutions implementing these intelligent applications. The products include the only “smart hemodialysis solution” in the country for patients with kidney diseases. Wistron Medical Technology published a number of papers about the clinical benefits of smart hemodialysis solutions at the Kidney Medical Association in 2019. After widespread repercussions, in response to the incidence of end-stage renal disease in the country and the current status of health care expenditures, WMT plans to extend this solution to chronic kidney disease (CKD) patient care management and other chronic disease care, including hypertension and diabetes, to create a chronic disease care platform. At the same time, Wistron Medical Technology's strong software development team develops health-facilitation solutions and smart hospital applications, and builds digitalized clinical processes, and moves towards medical intelligence to gradually outline the future hospital ecosystem.

Wistron Medical Technology further leverages its capability of data analysis and software development, upholding the belief of putting people's benefits first, to introduce intelligent systems and optimize the clinical operation process in hospitals. The products includes: through machine learning, accurately providing clinical professions with the international disease classification standard code "ICD-10 "CM Intelligent Recommendation System", the "Intelligent Medical Speech Platform" supporting Chinese and English voice input, the "non-contact physiological information system" for remote wireless monitoring of breathing and heartbeat, and finally the "liver tumor AI platform" for medical imaging. By working with the clinics, the products will benefit the health of the people, and have a great impact in SaMD (Software as a Medical Device) market.

Creating Innovative Medical Devices by Software and Hardware Integration 

Wistron Medical Technology develops medical devices  spanning from in vitro diagnostic devices to medical imaging equipment. In terms of cancer cell screening, the team integrated photoelectromechanical and ultra-microfluidic technology to detect the number of circulating tumor cells in the blood through microfluidic wafers as indicators of cancer. In the field of genetic testing, WMT also cooperated with Spartan Bioscience in Canada to develop the world's smallest palm-sized molecular detection instrument that can easily perform complex detection on site, improving the convenience and feasibility of precision medicine and environmental testing. At the same time, it develops and manufactures with leading customers, the world's lightest machine assistive device, providing a glimmer of light for those with difficult mobility.